SPOG has just launched the INTER-EWING-1 international clinical trial at the first member hospital. This study aims to use improved treatment methods to reduce the high relapse rate in people with Ewing sarcoma and to increase survival rates.
Ewing sarcoma is a malignant tumour that usually affects the bones. It occurs most often in adolescents and young adults. Although treatment methods have improved in recent years, the cancer returns in 30–40% of patients. With the INTER-EWING-1 clinical trial, researchers aim to reduce this high relapse rate and increase survival rates. To achieve this, the study is testing improved treatment methods.
Additional chemotherapy and adjusted radiation dose
Doctors are investigating whether an additional course of chemotherapy at the end of standard treatment, known as maintenance chemotherapy, can improve treatment outcomes. At the same time, they are examining whether an adjusted radiation dose could have a positive effect. The study also places a strong focus on patients’ quality of life: This includes surveys of both patients and their parents.
Each year in Switzerland, around 10 to 15 adolescents and young adults with Ewing sarcoma are expected to be eligible to take part in INTER-EWING-1. SPOG is pleased that the clinical trial is now open to patients.
Further information: INTER-EWING-1
Brigitte Casanova
Brigitte Casanova supports SPOG communication projects; as a Germanist, she complements the science-oriented team at the Coordination Center.
More articles from Brigitte Casanova
